s

What is an Anti-idiotypic Antibody?

s

Technical articles featuring applications of anti-idiotypic antibodies.

s

Request Bulk Quote
Follow us on:

Facebook Linkedin YouTube WeChat

Antibodies for bioanalysis and drug monitoring of burosumab

Develop highly selective and sensitive PK and ADA assays for the humanized antibody drug burosumab (Crysvita®) using our range of ready-made anti-idiotypic antibodies.

  • Highly specific to burosumab and the burosumab/human FGF-23-His complex
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch-to-batch consistency
  • Non-animal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies specific to burosumab.

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product

Details

Burosumab Inhibitory Type 1

TZA0109

AbD63869ad

Fab-F-Spy2-H1

0.4

PK bridging ELISA (capture)

Order TZA0109

TZA0110

AbD63865ad

Fab-F-Spy2-H1

0.1

PK bridging ELISA (detection)

Order TZA0110

TZA0110P

AbD63865pap

Fab2-FH-X22-HRP2

0.1

PK bridging ELISA (detection)

Order TZA0110P

Burosumab/hFGF-23-His Complex Specific Type 3

TZA0111

AbD64797ad

Fab-F-Spy2-H1

1

PK ELISA antigen capture format

Order TZA0111

TZA0111P

AbD64797pap

Fab2-FH-X22-HRP2

1

PK ELISA antigen capture format

Order TZA0111P

* Affinity measured in the monovalent Fab format.
1 Fab-F-Spy2-H = Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags.
2 Fab2-FH-X22-HRP = Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags, and Fab-SpyTag coupled to HRP-conjugated BiCatcher.

Anti-Burosumab Inhibitory Antibodies (Type 1)

Type 1 anti-burosumab antibodies inhibit the binding of the drug burosumab to its target, human fibroblast growth factor 23 (FGF-23). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug.

Anti-Burosumab/hFGF-23-His Complex Specific Antibodies (Type 3)

The Type 3 antibodies specifically recognize the drug-target complex, detecting burosumab only when it is bound to hFGF-23-His. They are suitable as a detection antibody in a PK antigen capture assay.

ELISA Protocols to Get You Started

PK Bridging ELISA

PK Bridging ELISA, Free Drug: TZA0109 (capture) and TZA0110/TZA0110P (detection)

Fig. 1. Burosumab PK bridging ELISA using antibodies TZA0109 (capture) and TZA0110P (detection).

Fig. 1. Burosumab PK bridging ELISA using antibodies TZA0109 (capture) and TZA0110P (detection).

Schematic image of PK bridging ELISA detecting free drug

Schematic image of PK bridging ELISA detecting free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple), labeled with HRP.

PK Antigen Capture ELISA

PK Antigen Capture ELISA: hFGF-23-His (capture) and TZA0111 (detection)

PK Antigen Capture ELISA: hFGF-23-His (capture) and TZA0111P (detection)

Fig. 2. Burosumab PK antigen capture ELISA using hFGF-23-His and TZA0111P.

Fig. 2. Burosumab PK antigen capture ELISA using hFGF-23-His and TZA0111P.

Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug target complex detection antibody, monovalent Fab format (purple), labeled with HRP.

Schematic image of PK antigen capture ELISA.  Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, monovalent Fab format (purple), labeled with HRP.

Resources

Anti-idiotypic antibodies, their binding types and properties

Anti-biotherapeutic antibody quality control and characterization

Custom anti-idiotypic antibody generation service

Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.